Development of spirulina for the manufacture and oral delivery of protein therapeutics.

Autor: Jester BW; Lumen Bioscience, Seattle, WA, USA., Zhao H; Lumen Bioscience, Seattle, WA, USA., Gewe M; Lumen Bioscience, Seattle, WA, USA., Adame T; Lumen Bioscience, Seattle, WA, USA., Perruzza L; Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland., Bolick DT; Division of Infectious Diseases & International Health, University of Virginia School of Medicine, Charlottesville, VA, USA., Agosti J; Lumen Bioscience, Seattle, WA, USA., Khuong N; Lumen Bioscience, Seattle, WA, USA., Kuestner R; Lumen Bioscience, Seattle, WA, USA., Gamble C; Lumen Bioscience, Seattle, WA, USA., Cruickshank K; Lumen Bioscience, Seattle, WA, USA., Ferrara J; Lumen Bioscience, Seattle, WA, USA., Lim R; Lumen Bioscience, Seattle, WA, USA., Paddock T; Lumen Bioscience, Seattle, WA, USA., Brady C; Lumen Bioscience, Seattle, WA, USA., Ertel S; Lumen Bioscience, Seattle, WA, USA., Zhang M; Lumen Bioscience, Seattle, WA, USA., Pollock A; Lumen Bioscience, Seattle, WA, USA., Lee J; Lumen Bioscience, Seattle, WA, USA., Xiong J; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA.; Merck & Co., West Point, PA, USA., Tasch M; Lumen Bioscience, Seattle, WA, USA., Saveria T; Lumen Bioscience, Seattle, WA, USA., Doughty D; Lumen Bioscience, Seattle, WA, USA., Marshall J; Lumen Bioscience, Seattle, WA, USA., Carrieri D; Lumen Bioscience, Seattle, WA, USA.; Sandia National Laboratories, Livermore, CA, USA., Goetsch L; Lumen Bioscience, Seattle, WA, USA., Dang J; Lumen Bioscience, Seattle, WA, USA., Sanjaya N; Lumen Bioscience, Seattle, WA, USA., Fletcher D; Lumen Bioscience, Seattle, WA, USA., Martinez A; Lumen Bioscience, Seattle, WA, USA., Kadis B; Lumen Bioscience, Seattle, WA, USA., Sigmar K; Lumen Bioscience, Seattle, WA, USA., Afreen E; Lumen Bioscience, Seattle, WA, USA., Nguyen T; Lumen Bioscience, Seattle, WA, USA., Randolph A; Lumen Bioscience, Seattle, WA, USA., Taber A; Lumen Bioscience, Seattle, WA, USA., Krzeszowski A; Lumen Bioscience, Seattle, WA, USA., Robinett B; Lumen Bioscience, Seattle, WA, USA., Volkin DB; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA., Grassi F; Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland., Guerrant R; Division of Infectious Diseases & International Health, University of Virginia School of Medicine, Charlottesville, VA, USA., Takeuchi R; Lumen Bioscience, Seattle, WA, USA.; TScan Therapeutics, Waltham, MA, USA., Finrow B; Lumen Bioscience, Seattle, WA, USA., Behnke C; Lumen Bioscience, Seattle, WA, USA., Roberts J; Lumen Bioscience, Seattle, WA, USA. jroberts@lumen.bio.
Jazyk: angličtina
Zdroj: Nature biotechnology [Nat Biotechnol] 2022 Jun; Vol. 40 (6), pp. 956-964. Date of Electronic Publication: 2022 Mar 21.
DOI: 10.1038/s41587-022-01249-7
Abstrakt: The use of the edible photosynthetic cyanobacterium Arthrospira platensis (spirulina) as a biomanufacturing platform has been limited by a lack of genetic tools. Here we report genetic engineering methods for stable, high-level expression of bioactive proteins in spirulina, including large-scale, indoor cultivation and downstream processing methods. Following targeted integration of exogenous genes into the spirulina chromosome (chr), encoded protein biopharmaceuticals can represent as much as 15% of total biomass, require no purification before oral delivery and are stable without refrigeration and protected during gastric transit when encapsulated within dry spirulina. Oral delivery of a spirulina-expressed antibody targeting campylobacter-a major cause of infant mortality in the developing world-prevents disease in mice, and a phase 1 clinical trial demonstrated safety for human administration. Spirulina provides an advantageous system for the manufacture of orally delivered therapeutic proteins by combining the safety of a food-based production host with the accessible genetic manipulation and high productivity of microbial platforms.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: